Table 2. Genotype distribution by treatment status.

rs12041331	Placebo	Aspirin	Total
GG	5,630 (82.7%)	5,647 (83.8%)	11,277 (83.2%)
GA	1,112 (16.3%)	1,034 (15.3%)	2,146 (15.8%)
AA	64 (0.9%)	60 (0.9%)	124 (0.9%)
	6,806	6,741	13,547

Genomewide single-nucleotide polymorphism genotyping of 14,177 samples collected by the ASPirin in Reducing Events in the Elderly (ASPREE) Healthy Ageing Biobank was performed using the Axiom 2.0 Precision Medicine Diversity Research Array (Thermo Fisher Scientific) following standard protocols. A total of 13,547 samples passed post-genotyping quality control (QC) filters. Samples were excluded based on filters related to sex discordance, genotyping rate (< 95%), relatedness, Hardy–Weinberg equilibrium, and ethnicity. Imputation was performed on European-ancestry samples using the haplotype reference consortium panel on the Michigan imputation server.²² Post-imputation QC removed all variants with < 0.3 imputation quality scores. The imputation quality score of the variant rs12041331 was R² = 0.99.